Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02454010 · ClinicalTrials.gov registry record · Phase 1

A Dose Escalation Study of Radio-labeled Antibody for the Treatment of Advanced Cancer

A Phase 1 study of Solid Tumor, sponsored by Fujifilm Pharmaceuticals U.S.A..

Completed
Registry status
Phase 1
Development phase
73
Enrollment target
4
Study locations

NCT02454010 is a Phase 1 study of Solid Tumor that has completed, run by Fujifilm Pharmaceuticals U.S.A.. The registered enrollment target is 73 participants, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (67% lower). The trial reports 4 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02454010, a Phase 1 study of Solid Tumor, has completed, sponsored by Fujifilm Pharmaceuticals U.S.A..

COMPLETED
Registry status
Phase 1
Development phase
73 participants
Enrollment target
4
Study locations

Study Summary

The purpose of this study is to determine the safety and tolerability in subjects who receive FF-21101(111In) for dosimetry and FF-21101(90Y) for treatment of advanced solid tumors.

Conditions Studied

Solid Tumor

Interventions

  • BIOLOGICAL FF21101

Study Locations (4)

Georgia

  • Winship Cancer Institute - Emory University - Atlanta

Illinois

  • Northwestern University - Feinberg School of Medicine - Chicago

Oklahoma

  • Stephenson Cancer Center - Oklahoma City

Texas

  • University of Texas M.D. Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 73 participants
Start Date 2016-01
Est. Completion 2021-10
Phase Phase 1

Sponsor

Fujifilm Pharmaceuticals U.S.A.

8 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02454010

The ClinicalTrials.gov registry entry for NCT02454010 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 73 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (67% lower). The listed sponsor is Fujifilm Pharmaceuticals U.S.A., which has 8 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which FF21101 is the first listed.

NCT02454010 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Georgia, Illinois, Oklahoma.

Frequently Asked Questions

What is clinical trial NCT02454010 about?

NCT02454010 is a clinical study titled "A Dose Escalation Study of Radio-labeled Antibody for the Treatment of Advanced Cancer". The purpose of this study is to determine the safety and tolerability in subjects who receive FF-21101(111In) for dosimetry and FF-21101(90Y) for treatment of advanced solid tumors.

What is the current status of trial NCT02454010?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 73 participants. The study started on 2016-01. Estimated completion is 2021-10.

What conditions does trial NCT02454010 study?

This clinical trial studies the following conditions: Solid Tumor.

What interventions are being tested in trial NCT02454010?

The interventions under investigation include: FF21101 (BIOLOGICAL).

Who is sponsoring clinical trial NCT02454010?

This trial is sponsored by Fujifilm Pharmaceuticals U.S.A., which has 8 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02454010 being conducted?

This trial has 4 study locations across Georgia, Illinois, Oklahoma, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Solid Tumor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Solid Tumor

All registered trials for this condition

Georgia

All trials with a study site in Georgia

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.